Comparative Safety and Tolerability of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension

CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 Polymorphisms in Patients With Bosentan-Induced Liver Toxicity

(2014) M Roustit et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients

(2014) Gérald Simonneau et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes

(2014) Eve-Irene Lepist et al.   PLoS One

The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension

(2014) Alexandru Steriade et al.   Therapeutic Advances in Respiratory Disease

Macitentan: First Global Approval

(2013) Trina Patel et al.   DRUGS

Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

(2013) Jasper Dingemanse et al.   Expert Opinion On Drug Safety

Updated Treatment Algorithm of Pulmonary Arterial Hypertension

(2013) Nazzareno Galiè et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Updated Clinical Classification of Pulmonary Hypertension

(2013) Gerald Simonneau et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

(2013) Tomás Pulido et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequency of Edema in Patients With Pulmonary Arterial Hypertension Receiving Ambrisentan

(2012) Shelley Shapiro et al.   AMERICAN JOURNAL OF CARDIOLOGY

Endothelin Axis Is Upregulated in Human and Rat Right Ventricular Hypertrophy

(2012) Jayan Nagendran et al.   CIRCULATION RESEARCH

Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension

(2012) L. Savale et al.   EUROPEAN RESPIRATORY JOURNAL

Long-Term Hepatic Safety of Ambrisentan in Patients With Pulmonary Arterial Hypertension

(2012) Ori Ben-Yehuda et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice

(2012) Lowell Ling et al.   LIFE SCIENCES

An update on the use of ambrisentan in pulmonary arterial hypertension

(2012) Michele D’Alto   Therapeutic Advances in Respiratory Disease

Pharmacokinetic evaluation of ambrisentan

(2011) Mitchell S Buckley et al.   Expert Opinion on Drug Metabolism & Toxicology

Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies

(2010) Robyn J. Barst et al.   BRITISH JOURNAL OF HAEMATOLOGY

Basic Science of Pulmonary Arterial Hypertension for Clinicians

(2010) Stephen L. Archer et al.   CIRCULATION

The Bile Salt Export Pump: Clinical and Experimental Aspects of Genetic and Acquired Cholestatic Liver Disease

(2010) Ping Lam et al.   SEMINARS IN LIVER DISEASE

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers

(2009) Rebecca Spence et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension

(2009) Ronald J. Oudiz et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension

(2008) Raymond L. Benza et al.   CHEST

Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities

(2008) Michael D. McGoon et al.   CHEST

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

(2008) Nazzareno Galiè et al.   CIRCULATION

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

(2008) N Galiè et al.   LANCET

Longer-term bosentan therapy improves functional capacity in Eisenmenger syndrome: Results of the BREATHE-5 open-label extension study

(2007) Michael A. Gatzoulis et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY